Telix Pharmaceuticals Limited
T3X.F
9.55 EUR
1 day: +0.89% (+0.08 EUR)
The alert is saved directly without jumping back to the homepage.
Price alerts for T3X.F
Please log in to view and save price alerts.
Finanzen
Company info
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Aktuelle News
-
Telix Pharmaceuticals Stock Leads 3 Fast Growing Insider Owned Shares
Vorschau anzeigen
Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real revenue, and management teams that are confident enough to back their own outlook with meaningful share ownership. This article walks through three fast growing stocks with high insider ownership that fit that brief. The three stocks below are just a...
-
Telix Pharmaceuticals Limited Q2 2026 Earnings Call Summary
Vorschau anzeigen
Moby summary of Telix Pharmaceuticals Limited's Q2 2026 earnings call
-
Telix Pharmaceuticals Ltd (TLPPF) (H1 2026) Earnings Call Highlights: Revenue Surges 22% to ...
Vorschau anzeigen
Telix Pharmaceuticals Ltd (TLPPF) reports strong first-half results with EBITDA up 146%, while navigating regulatory hurdles and competitive pressures in the PSMA imaging market.
-
Telix Pharmaceuticals H1 Earnings Call Highlights
Vorschau anzeigen
Telix Pharmaceuticals (NASDAQ:TLX) reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $3
-
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Vorschau anzeigen
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance1: Double-digit revenue growth and gross margin improvement Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.Group gross margin of 55%, up 2% year-over